Guidelines provide for the simplified deregistration procedure

In 2023, the healthcare industry in China was subject to significant legislative advancements and reforms aimed at addressing industry concerns and promoting innovation. Hanshuo Zhou and Xiaoyun Wang of Jingtian & Gongcheng summarize the key events, and provide a reflective review based on their' practical experience

Shanghai plans a three-tiered cross-border data flow regime in the Lingang free trade zone to boost foreign investment; the U.S. proposes a "know your customer" regulation for cloud computing companies over China AI concerns; and a bill introduced in Congress called the BIOSECURE Act, is designed to broaden current sanctions on China

Total asset requirements of main promoters of financial leasing companies are increased

Shenzhen expands the scope of PE investments. CSRC clarifies M&A thresholds. Guidelines promote the revision of basic cloud computing standards

Jiangsu publishes the first guidelines on handling criminal cases involving trade secret infringement.

Specific key data may be determined by the relevant authority in data transfer within the Greater Bay Area

U.S. Commerce official expects higher penalties for violations of U.S. export controls; Shein must satisfy both the U.S. and China to pull off its IPO; and U.S. lawmakers work to further limit U.S. investment in Chinese tech sector.

In 2023, significant U.S. restrictions were placed on Chinese interests. Charles Wu of Clyde & Co reviews the legislative changes, and offers practical insights into their potential impact, and the path forward in 2024